z-logo
Premium
Provision of KEL 1‐negative blood to obstetric patients: a 3‐year single‐institution retrospective review
Author(s) -
O'Brien Kerry L.,
Kim Yeowon A.,
Haspel Richard L.,
Uhl Lynne
Publication year - 2015
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.12814
Subject(s) - medicine , obstetrics , gestational age , pregnancy , blood transfusion , obstetric history , fetus , pediatrics , retrospective cohort study , gestation , immunology , surgery , genetics , biology
Background KEL 1 alloimmunization is a major cause of hemolytic disease of the fetus and newborn ( HDFN ). While select countries have guidelines for preventing transfusion‐associated KEL 1 alloimmunization, the U nited S tates does not. B eth I srael D eaconess M edical C enter instituted a policy in A pril 2009 whereby women not more than 50 years of age on the obstetric service were transfused KEL 1‐negative red blood cells ( RBC s). We sought to determine compliance and impact for prevention of KEL 1 alloimmunization and HDFN . Study Design and Methods All women not more than 50 years of age without anti‐ K transfused RBC s during an obstetric admission from A pril 9, 2009, to A pril 9, 2012, were identified (227). Adherence to policy, factors contributing to nonadherence, and subsequent impact were evaluated. For comparison, all cases of anti‐ K detection in women not more than 50 years of age admitted to nonobstetric services and all cases of transfusion‐associated KEL 1 alloimmunization in women not more than 50 years of age during the 10 years prior were identified. Results Eighty‐four percent received only KEL 1‐negative units. Three (1.3%) women not more than 50 years of age on the obstetric service were identified with anti‐ K , while 17 (1.5%) women not more than 50 years of age on nonobstetric services had anti‐ K detected; only five of 20 had a prior RBC transfusion. In the 10 years prior, there were 27 cases of transfusion‐associated KEL 1 alloimmunization in women not more than 50 years of age. There were no cases of KEL 1 HDFN in either period. Conclusion Although the findings demonstrate feasibility of providing KEL 1‐negative RBC s to women of childbearing potential, evidence for clinical benefit is lacking. The low prevalence of KEL 1 in blood donors, the lack of significant differences in alloimmunization rates, and no cases of HDFN during the study period questions the clinical benefit of such a policy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom